October 28 2005
VEENENDAAL, THE NETHERLANDS – Nucletron B.V., a global leader providing some of the world’s most innovative products and services for cancer treatment, has received 510(k) clearance from the U.S. Food and Drug Administration for Oncentra ConeBeam. Oncentra ConeBeam is a break-through method of acquiring and reconstructing CT images from 3D isotropic data. Used in conjunction with the Simulix Evolution simulator, Oncentra ConeBeam creates a unique radiation therapy imaging tool that can perform conventional and CT assisted simulation on the same platform, providing clinicians the best of both techniques. “We are using our experience from around the world to develop relevant clinical tools,” said David Imperiali, Managing Director of Nucletron. “Oncentra ConeBeam offers the oncology team the opportunity to more easily incorporate CT images in radiation treatment planning. We aim to provide imaging techniques that improve precision and productivity." Greater Baltimore Medical Center, Baltimore, Maryland is the first site in the United States using Oncentra ConeBeam clinically. As part of a gamma test, the Center has shown good results with cone beam CT imaging for both breast, and head and neck in treatment planning. Dr. Robert Brookland, Director of Radiation Oncology at Greater Baltimore Medical Center, Baltimore, MD states, "We are pleased with the new Oncentra ConeBeam imaging system installed on our Simulix Evolution. For our breast cancer patients we are able to perform digital fluoroscopy and acquire a volume of CT data with the patient in the true treatment position. Oncentra ConeBeam allows us to create a 3D treatment plan, optimizing the dose and providing a better treatment planning outcome. Our center is a long standing Simulix user and the addition of Oncentra ConeBeam further demonstrates Nucletron’s commitment to keeping its customers on the forefront of technology through upgrade opportunities.” About Greater Baltimore Medical The Greater Baltimore Medical Center is a not-for-profit, 372 bed community hospital providing innovative and comprehensive services in surgery, women’s health and cancer. Most recently GBMC was recognized by US World and News Report as one of America’s best hospital’s for cancer care. The Radiation Oncology Department treats over 80 patients per day and Dr. Robert Brookland is board certified and a fellow of the American College of Radiation Oncology. About Nucletron B.V. Nucletron is a global leader in the development, manufacture, sales, service and support of the world’s most innovative products for cancer treatment, with particular expertise in treatment planning systems, brachytherapy, simulation, integrated software solutions for oncology, and comprehensive support and professional education and services. The company has over 20 offices worldwide, including its corporate headquarters in Veenendaal, the Netherlands. For more information on Nucletron, please visit: http://www.nucletron.com/. Nucletron B.V. is a subsidiary of Delft Instruments. Delft Instruments is the holding company of an international group of companies, which hold a leading position in their respective markets with high quality, high technology products and services. Delft Instruments is active through wholly owned subsidiaries in more than 30 countries worldwide, employs approximately 1,000 people and reported turnover of EUR 261.6 million in 2004. For more information on Delft Instruments, please visit: http://www.delftinstruments.com/.
For further information: